<!--

File produced by pipelineRunner package (for JATS 2 SCJATS with pipeline SCJATS)
At: 2025-05-23T10:43:42.692Z

Version        : 1.16.1
Last update    : 2024-08-27
Modified by    : dunnm

-->
<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="correction"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Radiat Res</journal-id><journal-id journal-id-type="iso-abbrev">J Radiat Res</journal-id><journal-id journal-id-type="publisher-id">jrr</journal-id><journal-title-group><journal-title>Journal of Radiation Research</journal-title></journal-title-group><issn pub-type="ppub">0449-3060</issn><issn pub-type="epub">1349-9157</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40341922</article-id><article-id pub-id-type="pmc">PMC12100481</article-id><article-id pub-id-type="doi">10.1093/jrr/rraf017</article-id><article-id pub-id-type="publisher-id">rraf017</article-id><article-categories><subj-group subj-group-type="heading"><subject>Correction</subject></subj-group><subj-group subj-group-type="category-taxonomy-collection"><subject>AcademicSubjects/MED00870</subject><subject>AcademicSubjects/SCI00960</subject></subj-group></article-categories><title-group><article-title>Correction to: Prostate dose escalation may positively impact survival in patients with clinically node-positive prostate cancer definitively treated by radiotherapy: surveillance study of the Japanese Radiation Oncology Study Group (JROSG)</article-title></title-group><pub-date pub-type="collection"><month>5</month><year>2025</year></pub-date><pub-date pub-type="epub" iso-8601-date="2025-05-09"><day>09</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>09</day><month>5</month><year>2025</year></pub-date><volume>66</volume><issue>3</issue><fpage>341</fpage><lpage>342</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2025. Published by Oxford University Press on behalf of The Japanese Radiation Research Society and Japanese Society for Radiation Oncology.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="rraf017.pdf"/><related-article related-article-type="corrected-article" ext-link-type="doi" id="RA1" xlink:href="10.1093/jrr/rraf005"/><counts><page-count count="2"/></counts></article-meta></front><body><p>This is a correction to: Toshiya Maebayashi, Takashi Mizowaki, Hitoshi Ishikawa, Kiyonao Nakamura, Koji Inaba, Hirofumi Asakura, Hiromitsu Iwata, Satoshi Itasaka, Hiroyuki Wada, Masakuni Sakaguchi, Keiichi Jingu, Takeshi Akiba, Natsuo Tomita, Katsumasa Nakamura, Japanese Radiation Oncology Study Group, Prostate dose escalation may positively impact survival in patients with clinically node-positive prostate cancer definitively treated by radiotherapy: surveillance study of the Japanese Radiation Oncology Study Group (JROSG), <italic toggle="yes">Journal of Radiation Research</italic>, 2025; <ext-link xlink:href="https://doi.org/10.1093/jrr/rraf005" ext-link-type="uri">https://doi.org/10.1093/jrr/rraf005</ext-link></p><p>In the originally published version of the manuscript marked, emendations to Table 6 had been missed. These are now been emended in the article.</p><p>Table 6 should read:</p><table-wrap position="float" id="TB6"><label>Table 6</label><caption><p>Site of Recurrence in 148 patients with cT1-4N1M0 prostate cancer after radiotherapy experiencing clinical recurrence during follow-up</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Site (s) of recurrence (%)</th><th align="left" rowspan="1" colspan="1">Local recurrence (<italic toggle="yes">n</italic>&#x02009;=&#x02009;2; 1.4%)</th><th align="left" rowspan="1" colspan="1">Regional lymph nodes recurrence</th><th align="left" rowspan="1" colspan="1">Distant lymph nodes recurrence</th><th align="left" rowspan="1" colspan="1">Skeletal recurrence (<italic toggle="yes">n</italic>&#x02009;=&#x02009;17; 11.5%)</th><th align="left" rowspan="1" colspan="1">Visceral recurrence and others</th></tr><tr><th rowspan="1" colspan="1">&#x000a0;</th><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="left" rowspan="1" colspan="1">(<italic toggle="yes">n</italic>&#x02009;=&#x02009;7; 4.7%)</th><th align="left" rowspan="1" colspan="1">(<italic toggle="yes">n</italic>&#x02009;=&#x02009;2; 1.4%)</th><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="left" rowspan="1" colspan="1">(<italic toggle="yes">n</italic>&#x02009;=&#x02009;7; 4.7%)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Local region, lung, liver, bone and distant lymph nodes (%)</td><td align="left" rowspan="1" colspan="1">1 (50.0)</td><td align="left" rowspan="1" colspan="1">1 (14.3)</td><td align="left" rowspan="1" colspan="1">1 (50)</td><td align="left" rowspan="1" colspan="1">1 (5.9)</td><td align="left" rowspan="1" colspan="1">1 (14.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">Local region and regional lymph nodes (%)</td><td align="left" rowspan="1" colspan="1">1 (50.0)</td><td align="left" rowspan="1" colspan="1">1 (14.3)</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1">Regional lymph nodes only (%)</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">5 (71.4)</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1">Distant lymph nodes and bone (%)</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">1 (50)</td><td align="left" rowspan="1" colspan="1">1 (5.9)</td><td align="left" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1">Bone only (%)</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">14 (82.3)</td><td align="left" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1">Bone, lung and liver (%)</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">1 (5.9)</td><td align="left" rowspan="1" colspan="1">1 (14.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">Lung only (%)</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">2 (28.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">Other sites (excluding prostate, bones, regional lymph nodes, and lungs) (%)</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">3 (42.9)</td></tr></tbody></table></table-wrap><p>instead of:</p><table-wrap position="float" id="TB6a"><label>Table 6</label><caption><p>Site of Recurrence in 148 patients with cT1-4N1M0 prostate cancer after radiotherapy experiencing clinical recurrence during follow-up</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1">Site (s) of recurrence (%)</th><th align="center" rowspan="1" colspan="1">Local recurrence<break/> (<italic toggle="yes">n</italic>&#x02009;=&#x02009;2; 1.4%)</th><th align="center" rowspan="1" colspan="1">Regional lymph nodes recurrence<break/> (<italic toggle="yes">n</italic>&#x02009;=&#x02009;7; 4.7%)</th><th align="center" rowspan="1" colspan="1">Distant lymph nodes recurrence<break/> (<italic toggle="yes">n</italic>&#x02009;=&#x02009;2; 1.4%)</th><th align="center" rowspan="1" colspan="1">Skeletal recurrence<break/> (<italic toggle="yes">n</italic>&#x02009;=&#x02009;17; 11.5%)</th><th align="center" rowspan="1" colspan="1">Visceral recurrence and others<break/> (<italic toggle="yes">n</italic>&#x02009;=&#x02009;7; 4.7%)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Local region, lung, liver, bone and distant lymph nodes (%)<break/>Local region and regional lymph nodes (%)<break/>Regional lymph nodes only (%)<break/>Distant lymph nodes and bone (%)<break/>Bone only (%)<break/>Bone, lung and liver (%)<break/>Lung only (%)<break/>Other sites (excluding prostate, bones, regional lymph nodes, and lungs) (%)</td><td align="center" rowspan="1" colspan="1">1 (50.0)<break/>1 (50.0)<break/>-<break/>-<break/>-<break/>-<break/>-<break/>-</td><td align="center" rowspan="1" colspan="1">1 (14.3)<break/>1 (14.3)<break/>5 (71.4)<break/>-<break/>-<break/>-<break/>-<break/>-</td><td align="center" rowspan="1" colspan="1">1 (50)<break/>-<break/>-<break/>1 (50)<break/>-<break/>-<break/>-<break/>-</td><td align="center" rowspan="1" colspan="1">1 (5.9)<break/>-<break/>-<break/>1 (5.9)<break/>14 (82.3)<break/>1 (5.9)<break/>-<break/>-</td><td align="center" rowspan="1" colspan="1">1 (14.3)<break/>-<break/>-<break/>-<break/>-<break/>1 (14.3)<break/>2 (28.6)<break/>3 (42.9)</td></tr></tbody></table></table-wrap></body></article>